|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.
With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies.
Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focuses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
ICON Establishes University Scholarship Programme to Provide Increased Opportunities for Underrepresented Groups to Study STEM-Related Courses
Dublin, Ireland – 22 June 2022 – ICON plc, (NASDAQ: ICLR) a global
provider of drug and device development and commercialisation services
to pharmaceutical, biotechnology, medical device, and government
organisations, today announces that it has established a scholarship
programme to provide students from underrepresented groups increased
opportunities to access third level education.
More info >> |
|
 |
White Papers |
 |
|
Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling
Sartorius Group
The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >> |
|
|
.jpg)
